JUN 30, 2016 07:30 AM PDT

Proteome centric precision medicine: embracing pathological diversity

Speakers
  • Director, Advanced Clinical Biosystems Research Institute and Director of the Basic Science Research of the Barbra Streisand Woman's Heart Center
    Biography

      Dr. Van Eyk, Ph.D., is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. The institute mandate is to facilitate application of proteomics throughout medicine and enhance translation of new therapies and biomarkers to clinical use through the application of innovative technologies. Her research laboratory studies the underlying molecular mechanism of heart and vascular disease using a large number of proteomic methodologies focusing on the site-specific identification and quantification of disease induced post-translational modifications. The underlying concept of competitive post-translational modifications that act as molecular switches that sense and respond to dynamic changes within the cell.


      Widely regarded as an international leader in the field of proteomics, Van Eyk is best known for developing a number of lab tests to determine the presence of certain proteins or amino acids in patients' blood, which could indicate whether they have experienced a heart attack or have heart disease. She earned her Bachelor of Science degree in biology and chemistry at the University of Waterloo, Canada and her doctorate in biochemistry at the University of Alberta, Edmonton. During her directorship of the Johns Hopkins National Heart, Lung, and Blood Institute Proteomics Center, a National Heart, Lung, and Blood Institute Proteomics Center located at the Johns Hopkins University School of Medicine, Van Eyk also served as director of the Bayview Proteomics Group and as professor of medicine in the Division of Cardiology in Biological Chemistry and Biomedical Engineering. She has over 210 peer reviewed manuscripts, reviews, book chapters and has co-edited two books.


    Abstract:
    Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways.  Personalized medicine requires diagnosing a specific individual’s disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. This concept has driven decision-making processes around new drug trials that take into account altered pathological proteomes.  Furthermore, this work has led us to consider the need for continuous patent-centric biomarker analysis at the population level. We will share our work on developing technical pipelines for health and pathological discovery and targeted proteomic analysis that reduces the barriers around gender, age and social economic status. We have begun down this path with production of system suitability and quality control measures, development of quantitative small and large multiplex assays and will discuss the remaining challenges involved and requirement for population-scale proteomics.

    Learning Objectives:
    • Understand the underlying premise that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease
    • See data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy

    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    Loading Comments...